MIM
Monashee Investment Management Portfolio holdings
AUM
$190M
This Quarter Return
+2.26%
1 Year Return
+42.84%
3 Year Return
+185.9%
5 Year Return
+237.5%
10 Year Return
+2,730.86%
AUM
$773M
AUM Growth
+$773M
(-8.5%)
Cap. Flow
-$77.8M
Cap. Flow
% of AUM
-10.06%
Top 10 Holdings %
Top 10 Hldgs %
77.44%
Holding
147
New
42
Increased
10
Reduced
17
Closed
69
Top Buys
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
$11.8M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
$11.3M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
$11.2M |
| 4 |
Birkenstock
BIRK
|
$10.9M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
$10M |
Top Sells
| 1 |
AB InBev
BUD
|
$16.4M |
| 2 |
SharkNinja
SN
|
$14.8M |
| 3 |
Kaspi.kz JSC
KSPI
|
$11.2M |
| 4 |
ODDITY Tech
ODD
|
$8.91M |
| 5 |
GE Aerospace
GE
|
$8.43M |
Sector Composition
| 1 | Healthcare | 6.59% |
| 2 | Technology | 4.5% |
| 3 | Industrials | 3.66% |
| 4 | Financials | 3.35% |
| 5 | Consumer Discretionary | 2.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Olema Pharmaceuticals
OLMA
$432M
| – | – |
-135,000
| Closed | -$1.53M |
|
|
102
ODDITY Tech
ODD
$3.39B
| – | – |
-205,000
| Closed | -$8.91M |
|
103
Napco Security Technologies
NSSC
$1.42B
| – | – |
-90,000
| Closed | -$3.61M |
|
104
Nasdaq
NDAQ
$53.8B
| – | – |
-105,000
| Closed | -$6.63M |
|
105
Nuveen Churchill Direct Lending
NCDL
$782M
| – | – |
-95,963
| Closed | -$1.73M |
|
106
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| – | – |
-31,189
| Closed | -$344K |
|
|
107
NewAmsterdam Pharma
NAMS
$2.8B
| – | – |
-170,000
| Closed | -$4.02M |
|
108
ADC Therapeutics
ADCT
$370M
| – | – |
-500,000
| Closed | -$2.25M |
|
109
Absci
ABSI
$356M
| – | – |
-500,000
| Closed | -$2.84M |
|
110
ADT
ADT
$7.11B
| – | – |
-320,000
| Closed | -$2.15M |
|
111
Aquestive Therapeutics
AQST
$478M
| – | – |
-1,000,000
| Closed | -$4.26M |
|
112
Arcutis Biotherapeutics
ARQT
$1.91B
| – | – |
-380,000
| Closed | -$3.77M |
|
113
Atmus Filtration Technologies
ATMU
$3.67B
| – | – |
-100,000
| Closed | -$3.23M |
|
|
AUTL
114
Autolus Therapeutics
AUTL
$383M
| – | – |
-492,000
| Closed | -$3.14M |
|
115
BridgeBio Pharma
BBIO
$9.91B
| – | – |
-60,000
| Closed | -$1.86M |
|
116
Bilibili
BILI
$9.2B
| – | – |
-175,000
| Closed | -$1.96M |
|
117
Dutch Bros
BROS
$9.1B
| – | – |
-50,000
| Closed | -$1.65M |
|
|
118
AB InBev
BUD
$116B
| – | – |
-270,100
| Closed | -$16.4M |
|
119
Bowman Consulting
BWMN
$715M
| – | – |
-25,000
| Closed | -$870K |
|
120
Cardlytics
CDLX
$47.4M
| – | – |
-75,000
| Closed | -$1.09M |
|
121
Cadre Holdings
CDRE
$1.24B
| – | – |
-60,000
| Closed | -$2.17M |
|
122
CG Oncology
CGON
$2.19B
| – | – |
-125,000
| Closed | -$5.49M |
|
123
Chewy
CHWY
$16.8B
| – | – |
-200,000
| Closed | -$3.18M |
|
124
Celldex Therapeutics
CLDX
$1.57B
| – | – |
-87,500
| Closed | -$3.67M |
|
125
Dynatrace
DT
$15.1B
| – | – |
-35,000
| Closed | -$1.63M |
|